Argenta Discovery, Etiologics deal
Argenta and Etiologics have merged to form a company that offers contract research services and has respiratory and inflammation compounds in preclinical development. Argenta brings expertise in medicinal, synthetic and analytical chemistry as well as biochemistry and computational techniques to the new company, which will be called Argenta Discovery. Etiologics brings biology and pharmacology expertise, plus several preclinical compounds to treat the symptoms and progression of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The new company will take compounds through Phase IIa studies before partnering. Argenta's sales were £6.7 million ($11.7 million) in the 12 months to March 31. ...